Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anastrozole and DHB Interaction: Compatible | Peptide Database

Compound Profiles Anastrozole Aromatase Inhibitor | Estrogen Management Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

DHB

Injectable Anabolic Steroid | Lean Mass Alternative to Primobolan

DHB exerts its anabolic effects through direct binding to the androgen receptor (AR) with high affinity. As a 5-alpha reduced steroid, DHB cannot be further reduced by 5-alpha reductase and is not a substrate for aromatase, meaning it does not convert to estradiol or any estrogenic metabolite.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anastrozole with DHB?

Yes, Anastrozole and DHB can generally be taken together. Aromatase inhibitors are generally less necessary when DHB is part of a stack because DHB itself does not aromatize. AI requirements are determined entirely by the testosterone dose in the protocol. Some users find they can run a higher testosterone dose alongside DHB without needing as aggressive an AI approach as they would with other aromatizing compounds stacked on top of testosterone.

Is Anastrozole and DHB safe together?

Based on documented research, this combination is considered compatible. However, shared safety flags include: androgenic, estrogenic, hepatotoxic, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between Anastrozole and DHB?

Aromatase inhibitors are generally less necessary when DHB is part of a stack because DHB itself does not aromatize. AI requirements are determined entirely by the testosterone dose in the protocol. Some users find they can run a higher testosterone dose alongside DHB without needing as aggressive an AI approach as they would with other aromatizing compounds stacked on top of testosterone. This assessment has 90% confidence and is based on documented research data.

How should I time Anastrozole and DHB?

Anastrozole has a half-life of ~40-50 hours and DHB has a half-life of ~7-9 days (cypionate ester). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Irreversibly inactivates aromatase to reduce estradiol levels during testosterone or aromatizable anabolic steroid cycles. The absence of estrogen rebound makes exemestane particularly useful when discontinuing AI support, such as transitioning into PCT. Manages estrogen-mediated fluid retention and subcutaneous bloating common with testosterone and other aromatizable compounds. The mild androgenic activity of exemestane may complement the drier appearance. Titrated to keep estradiol within a healthy range during hormone replacement or enhancement protocols. Because inhibition is irreversible, overshooting the dose requires waiting for new aromatase synthesis rather than simply skipping doses. Bloodwork is essential. FDA-approved for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy, and as adjuvant therapy after 2-3 years of tamoxifen. The IES trial demonstrated improved disease-free survival when switching to exemestane after initial tamoxifen treatment. Used off-label alongside TRT to manage estradiol elevations. The irreversible mechanism and mild androgenic properties make it an alternative to anastrozole for men who experience excessive joint pain or mood disturbance on nonsteroidal AIs. Exemestane's irreversible mechanism prevents the estrogen rebound that can occur when stopping a reversible AI like anastrozole at the end of a cycle. This makes it well-suited for managing estrogen during the transition into post-cycle therapy with SERMs.

Source: peptide-db.com ↗

Research Indications

FDA-approved indication. Stanozolol increases plasma levels of C1-esterase inhibitor and C4 complement, reducing the frequency and severity of angioedema episodes characterized by localized swelling of the skin, mucous membranes, and internal organs. Previously used to stimulate erythropoiesis in patients with aplastic anemia and other bone marrow failure states. Largely replaced by erythropoietin-stimulating agents and other modern therapies, though it demonstrated efficacy in stimulating red blood cell production. Widely used during caloric deficit phases to preserve lean mass and enhance muscle hardness, vascularity, and definition. The absence of water retention produces a dry, striated appearance that is highly valued in competitive bodybuilding. Provides significant increases in maximal and explosive strength without substantial body weight gain. Historically popular in weight-class-restricted sports, track and field, and combat sports for this reason. Enhances speed and power output through improved neuromuscular efficiency, increased red blood cell count, and enhanced protein synthesis. The lack of water weight gain is advantageous for athletes where power-to-weight ratio is critical. Anti-catabolic properties help preserve lean tissue during aggressive caloric restriction. The potent SHBG suppression enhances free testosterone levels, further supporting muscle preservation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent. General use 50-100 mcg 1-2x daily SubQ or IV Research protocols 100-200 mcg As directed

Source: peptide-db.com ↗
Side effects

Common Side Effects

Nausea (very common during initiation; typically resolves with continued use) Drowsiness and somnolence (often taken at bedtime to manage this) Dizziness or lightheadedness Headache Insomnia (in some users, despite drowsiness being more typical) Orthostatic hypotension (feeling faint when standing up quickly)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →